Professor of Medicine, University Tex Houston
Oncology
Dr. Jonathan M. Kurie, MD
|
|
Give Review
Jonathan Kurie is an expert in the field of Oncology. He graduated from Medical College of Georgia. He has 2 awards "Regional Top Doctor" and "Elected Member". Dr. Jonathan M. Kurie is a published MD as well. He has 65 publications published. The latest was: Human Lung Fibroblasts Inhibit Non-Small Cell Lung Cancer Metastasis in ExVivo 4D Model. He accepts Medicare payments and is registered with Medicare.gov.
Publications
- Human Lung Fibroblasts Inhibit Non-Small Cell Lung Cancer Metastasis in Ex Vivo 4D Model.
- Smoking, p53 mutation, and lung Cancer.
- Expression of TLR9 in tumor-infiltrating mononuclear cells enhances angiogenesis and is associated with a worse survival in lung Cancer.
- Comparing histone deacetylase inhibitor responses in genetically engineered mouse lung Cancer models and a window of opportunity trial in patients with lung Cancer.
- CXCR2 expression in tumor cells is a poor prognostic factor and promotes invasion and metastasis in Lung adenocarcinoma.
- A Synthetic Matrix with Independently Tunable Biochemistry and Mechanical Properties to Study Epithelial Morphogenesis and EMT in a Lung Adenocarcinoma Model.
- Human Lung Cancer Cells Grown in an Ex Vivo 3D Lung Model Produce Matrix Metalloproteinases Not Produced in 2D Culture.
- Human lung Cancer cells grown on acellular rat lung matrix create perfusable tumor nodules.
- Map2k4 Functions as a Tumor Suppressor in Lung Adenocarcinoma and Inhibits Tumor Cell Invasion by Decreasing Peroxisome Proliferator-Activated Receptor {gamma}2 Expres...
- Targets of the tumor suppressor miR-200 in regulation of the epithelial-mesenchymal transition in Cancer.
- Bexarotene Plus Erlotinib Suppress Lung Carcinogenesis Independent of KRAS Mutations in Two Clinical Trials and Transgenic Models.
- Cell Plasticity in Lung injury and repair: report from an NHLBI workshop, April 19-20, 2010.
- The Notch ligand Jagged2 promotes Lung adenocarcinoma metastasis through a miR-200-dependent pathway in mice.
- miR-200 Inhibits Lung adenocarcinoma cell invasion and metastasis by targeting Flt1/VEGFR1.
- Biological activity of celecoxib in the bronchial epithelium of current and former smokers.
- MKK4/SEK1 is negatively regulated through a feedback loop involving the E3 ubiquitin ligase itch.
- Contextual extraCellular cues promote tumor Cell EMT and metastasis by regulating miR-200 family expression.
- Tumor-specific apoptosis caused by deletion of the ERBB3 pseudo-kinase in mouse intestinal epithelium.
- Distinct biological roles for the notch ligands Jagged-1 and Jagged-2.
- Promotion of lung carcinogenesis by Chronic obstructive pulmonary disease-like airway inflammation in a K-ras-induced mouse model.
- Expression signatures of metastatic capacity in a genetic mouse model of Lung adenocarcinoma.
- Cyclic AMP-responsive element binding protein- and nuclear factor-kappaB-regulated CXC chemokine gene expression in Lung carcinogenesis.
- Identification of secreted proteins that mediate cell-cell interactions in an in vitro model of the lung Cancer microenvironment.
- Intratumoral epiregulin is a marker of advanced disease in non-small cell lung Cancer patients and confers invasive properties on EGFR-mutant cells.
- A new method for respiratory gating during microcomputed tomography of Lung in mice.
- Oral epithelium as a surrogate tissue for assessing smoking-induced molecular alterations in the Lungs.
- A selective small molecule inhibitor of c-Met, PHA-665752, reverses Lung premalignancy induced by mutant K-ras.
- Pten inactivation accelerates oncogenic K-ras-initiated tumorigenesis in a mouse model of lung Cancer.
- Phosphatidylinositol 3-kinase mediates bronchioalveolar stem cell expansion in mouse models of oncogenic K-ras-induced lung Cancer.
- Proliferative changes in the bronchial epithelium of former smokers treated with retinoids.
- Targeted deletion of MKK4 gene potentiates TNF-induced apoptosis through the down-regulation of NF-kappa B activation and NF-kappa B-regulated antiapoptotic gene produ...
- Drugging the bad "AKT-TOR" to overcome TKI-resistant lung Cancer.
- Lung premalignancy induced by mutant B-Raf, what is thy fate? To senesce or not to senesce, that is the question.
- Mitogen-activated protein kinase kinase-4 promotes Cell survival by decreasing PTEN expression through an NF kappa B-dependent pathway.
- Transcriptional profiling of non-small cell lung Cancer cells with activating EGFR somatic mutations.
- SRC-family kinases are activated in non-small cell lung Cancer and promote the survival of epidermal growth factor receptor-dependent cell lines.
- High expression of ligands for chemokine receptor CXCR2 in alveolar epithelial neoplasia induced by oncogenic kras.
- High expression of ErbB family members and their ligands in Lung adenocarcinomas that are sensitive to inhibition of epidermal growth factor receptor.
- Arsenic trioxide inhibits nuclear receptor function via SEK1/JNK-mediated RXRalpha phosphorylation.
- Murine Lung tumor measurement using respiratory-gated micro-computed tomography.
- Inhibition of mammalian target of rapamycin reverses alveolar epithelial neoplasia induced by oncogenic K-ras.
- c-Jun N-terminal kinase contributes to aberrant retinoid signaling in lung Cancer cells by phosphorylating and inducing proteasomal degradation of retinoic acid recept...
- Aberrant epidermal growth factor receptor signaling and enhanced sensitivity to EGFR inhibitors in lung Cancer.
- Immortalization of human bronchial epithelial Cells in the absence of viral oncoproteins.
- Role of protein kinase B-dependent signaling in Lung tumorigenesis.
- Deguelin-induced inhibition of cyclooxygenase-2 expression in human bronchial epithelial Cells.
- A big step in the study of small cell lung Cancer.
- Phase I study of weekly alternating therapy with irinotecan/cisplatin and etoposide/cisplatin for patients with small-cell lung Cancer.
- Dose-dense therapy with a novel irinotecan regimen for small-cell lung Cancer.
- Increased phospho-AKT (Ser(473)) expression in bronchial dysplasia: implications for lung Cancer prevention studies.
- Evidence that phosphatidylinositol 3-kinase- and mitogen-activated protein kinase kinase-4/c-Jun NH2-terminal kinase-dependent Pathways cooperate to maintain Lung canc...
- Cyclin D1 expression in the field of exposure: another piece in the molecular Auerbach puzzle.
- A phase I study of topotecan/paclitaxel alternating with etoposide/cisplatin and thoracic irradiation in patients with limited small cell lung Cancer.
- Treatment of former smokers with 9-cis-retinoic acid reverses loss of retinoic acid receptor-beta expression in the bronchial epithelium: results from a randomized pla...
- Induction of p53-regulated genes and tumor regression in lung Cancer patients after intratumoral delivery of adenoviral p53 (INGN 201) and radiation therapy.
- Inhibition of oncogenic K-ras signaling by aerosolized gene delivery in a mouse model of human lung Cancer.
- Interleukin-1 beta-mediated suppression of RXR:RAR transactivation of the Ntcp promoter is JNK-dependent.
- Initial clinical trial of oral TAC-101, a novel retinoic acid receptor-alpha selective retinoid, in patients with advanced Cancer.
- Loss of retinoic acid receptor beta gene expression is linked to aberrant histone H3 acetylation in lung Cancer cell lines.
- The novel and effective nonplatinum, nontaxane combination of gemcitabine and vinorelbine in advanced nonsmall cell Lung carcinoma: potential for decreased toxicity an...
- Insulin-like growth factor binding protein-3 inhibits the growth of non-small cell lung Cancer.
- Lack of PTEN expression in non-small cell lung Cancer could be related to promoter methylation.
- Expression of cyclooxygenase-1 and cyclooxygenase-2 in bronchial epithelium and nonsmall cell Lung carcinoma.
- The role of epithelial-mesenchymal transition programming in invasion and metastasis: a clinical perspective.
Schools
THE BRODY SCH OF MED AT E CAROLINA UNIV
Eugene Talmadge Meml Hospital
Procedures Preformed
- Thoracentesis
Conditions Treated
- Acute Leukemia
- Adrenal Gland Cancer
- Anemia
- Bladder Cancer
- View All
Doctors Specialties
- Medical Oncology
- Oncology
Accepted Insurances
Awards
- Regional Top Doctor
- Elected Member
Education
-
Memorial Sloan-Kettering Cancer Center -
Medical College of Georgia -
Brody School of Medicine at East Carolina University
Hospital
-
University of Texas M.D. Anderson Cancer Center
Drug Facts
| NPI NUMBER | 1679668321 | |
| NPPES Provider LastName | KURIE | |
| NPPES Provider FirstName | JONATHAN | |
| NPPES Provider ZIPCode | 770304009 | |
| NPPES Provider State | TX | |
| Specialty Description | Medical Oncology | |
| Total Claim Count | 139.0 | |
| Distinct Opioid Count | 1.0 | |
| Opioid Claim Count | 24.0 | |
| Percent Opioid Claims | 17.27 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1679668321 |
| Last Name Of The Provider | KURIE |
| First Name Of The Provider | JONATHAN |
| View All |
Similar Doctors
|
Dr. Nadya Hasham-Jiwa, DO
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Christopher J. Logothetis, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Saraswati P. Reddy, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. James C. Yao, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. Michael J. Overman, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. Michelle A. Fanale, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Gabriel N. Hortobagyi, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. David Hui, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. Abenaa M. Brewster, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Sindhu Nair, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Kanwal P. Raghav, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Robert Z. Orlowski, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. Cathy Eng, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Bryan T. Hennessy, MD
This Doctor is OpenDoctor Recommended.
|